KR102116303B1 - 안구 표면 질환 치료를 위한 제형 및 관련 방법 - Google Patents

안구 표면 질환 치료를 위한 제형 및 관련 방법 Download PDF

Info

Publication number
KR102116303B1
KR102116303B1 KR1020197016988A KR20197016988A KR102116303B1 KR 102116303 B1 KR102116303 B1 KR 102116303B1 KR 1020197016988 A KR1020197016988 A KR 1020197016988A KR 20197016988 A KR20197016988 A KR 20197016988A KR 102116303 B1 KR102116303 B1 KR 102116303B1
Authority
KR
South Korea
Prior art keywords
ambroxol
composition
present
weight
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197016988A
Other languages
English (en)
Korean (ko)
Other versions
KR20190085038A (ko
Inventor
밍우 왕
신디 에이. 왕
Original Assignee
밍우 왕
신디 에이. 왕
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 밍우 왕, 신디 에이. 왕 filed Critical 밍우 왕
Publication of KR20190085038A publication Critical patent/KR20190085038A/ko
Application granted granted Critical
Publication of KR102116303B1 publication Critical patent/KR102116303B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197016988A 2016-11-14 2017-11-10 안구 표면 질환 치료를 위한 제형 및 관련 방법 Active KR102116303B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662421822P 2016-11-14 2016-11-14
US62/421,822 2016-11-14
US201762463717P 2017-02-26 2017-02-26
US62/463,717 2017-02-26
PCT/US2017/061108 WO2018089797A1 (en) 2016-11-14 2017-11-10 Formulations for the treatment of ocular surface diseases and related methods

Publications (2)

Publication Number Publication Date
KR20190085038A KR20190085038A (ko) 2019-07-17
KR102116303B1 true KR102116303B1 (ko) 2020-05-29

Family

ID=62107036

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197016988A Active KR102116303B1 (ko) 2016-11-14 2017-11-10 안구 표면 질환 치료를 위한 제형 및 관련 방법

Country Status (9)

Country Link
US (5) US10265280B2 (enExample)
EP (1) EP3538083B1 (enExample)
JP (1) JP6871400B2 (enExample)
KR (1) KR102116303B1 (enExample)
CN (2) CN109982692A (enExample)
AU (1) AU2017357755B2 (enExample)
CA (1) CA3043327C (enExample)
ES (1) ES2988280T3 (enExample)
WO (1) WO2018089797A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108969511A (zh) * 2018-07-12 2018-12-11 图桑医疗科技（深圳）有限公司 溴已新及其衍生物在治疗和预防眼表疾病上的应用
US11326176B2 (en) 2019-11-22 2022-05-10 Mozza Foods, Inc. Recombinant micelle and method of in vivo assembly
US12359212B2 (en) 2019-11-22 2025-07-15 Mozza Foods, Inc. Recombinant micelle and method of in vivo assembly
CN112915090A (zh) * 2019-12-07 2021-06-08 王明武 用于治疗眼表疾病的一类化合物及其相关制剂和应用方法
AU2023277608A1 (en) * 2022-05-21 2024-11-28 Neuvision Development Llc Topical ocular administration of ambroxol for ocular pain

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU574360B2 (en) 1983-05-13 1988-07-07 Reichert, D. Antisnoring agent
DE3610997A1 (de) 1986-04-02 1987-10-15 Krewel Werke Gmbh Ambroxol-nasenspray
DE3731528A1 (de) * 1987-09-18 1989-04-13 Krewel Werke Gmbh Verwendung von trans-4- ((2-amino-3,5-dibrom-benzyl)-amino) -cyclohexanol zur lokalen behandlung von erkrankungen des auges
JPH08509725A (ja) 1993-04-30 1996-10-15 ザ、プロクター、エンド、ギャンブル、カンパニー コートされた医薬組成物
US5458879A (en) 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
IT1303671B1 (it) 1998-07-28 2001-02-23 Nicox Sa Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
AU770803B2 (en) 1998-12-23 2004-03-04 Idea Ag Improved formulation for topical non-invasive application in vivo
DE19933148A1 (de) 1999-07-20 2001-01-25 Boehringer Ingelheim Int Ambroxolhaltige Lutschtablette
US7179849B2 (en) 1999-12-15 2007-02-20 C. R. Bard, Inc. Antimicrobial compositions containing colloids of oligodynamic metals
CA2373171A1 (en) 2000-03-07 2001-09-13 Teijin Limited Stretch plaster
US20030216423A1 (en) 2000-05-24 2003-11-20 Sergio Ulloa Stable liquid and solid formulations
ITRM20010438A1 (it) * 2001-07-23 2003-01-23 Farmigea Spa Preparato oftalmico a base di n-acetilcisteina per il trattamento della sindrome dell'occhio secco.
DE10140320A1 (de) 2001-08-16 2003-03-06 Udo Zirfas Potenzfördernder und vitaltonisierender Wirkstoff
DE10203104A1 (de) 2002-01-25 2003-08-07 Boehringer Ingelheim Pharma Ambroxol für die Behandlung chronischer Schmerzen
US20030171391A1 (en) 2002-01-25 2003-09-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of chronic pain
DE10208313A1 (de) 2002-02-27 2003-09-11 Boehringer Ingelheim Pharma Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und Rachenraum
US20030166732A1 (en) 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
JP2004175749A (ja) * 2002-11-28 2004-06-24 Senju Pharmaceut Co Ltd ドライアイおよびドライアイを伴う疾病の治療剤
DE10332487A1 (de) 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen
DE10332486A1 (de) 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung akuter Schmerzen
DE10332473A1 (de) 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Epilepsie
AU2003904192A0 (en) * 2003-08-11 2003-08-21 Adelaide Research and Innovaiton Pty Ltd Method for inhibiting bacterial colonisation
KR20050036166A (ko) * 2003-10-15 2005-04-20 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 인두내 염증 치료용 암브록솔
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
DE102004021992A1 (de) 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topische Zubereitung enthaltend Ambroxol
CA2609549A1 (en) * 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
JP5337405B2 (ja) 2007-09-17 2013-11-06 ザ・ホスピタル・フォー・シック・チルドレン ゴーシェ病の治療方法
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
EP2793872B1 (en) 2011-12-22 2021-03-10 Centogene IP GmbH Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
CN102670607A (zh) 2012-05-28 2012-09-19 海南卫康制药(潜山)有限公司 复方盐酸氨溴索组合物及其制备方法
US20140235554A1 (en) * 2013-02-12 2014-08-21 Brian Lawrence Ophthalmic formulation derived from silk protein
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
AU2014309251B2 (en) 2013-08-23 2018-05-24 Parion Sciences, Inc. Dithiol mucolytic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment

Also Published As

Publication number Publication date
CN115607531A (zh) 2023-01-17
US20210046022A1 (en) 2021-02-18
JP6871400B2 (ja) 2021-05-12
AU2017357755B2 (en) 2019-06-13
WO2018089797A1 (en) 2018-05-17
EP3538083B1 (en) 2024-07-10
US20220378723A1 (en) 2022-12-01
US20180133173A1 (en) 2018-05-17
CA3043327A1 (en) 2018-05-17
AU2017357755A1 (en) 2019-05-30
US20190209496A1 (en) 2019-07-11
CN109982692A (zh) 2019-07-05
US10265280B2 (en) 2019-04-23
EP3538083A4 (en) 2020-05-27
ES2988280T3 (es) 2024-11-19
JP2019534335A (ja) 2019-11-28
US20240374540A1 (en) 2024-11-14
KR20190085038A (ko) 2019-07-17
CA3043327C (en) 2020-08-11
EP3538083A1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
CA2880027C (en) Progesterone compositions and treatment for eye diseases and disorders
KR102116303B1 (ko) 안구 표면 질환 치료를 위한 제형 및 관련 방법
EP2379078A2 (en) Topical formulations of flap inhibitors for administration to an eye
CN112915090A (zh) 用于治疗眼表疾病的一类化合物及其相关制剂和应用方法
TWI632913B (zh) 用於眼部疾病或異常之組合物及其治療方法
WO2006118170A1 (ja) 角膜疾患治療剤
CN105214092B (zh) 重组人白细胞介素-1受体拮抗剂及其组合物及药物用途
Halder et al. Efficacy and safety of bimatoprost 0.01% formulated in tight junction modulation technology compared to marketed benzalkonium chloride preserved bimatoprost 0.01% ophthalmic solution in healthy beagle dogs
KR20240130701A (ko) 알라닐-글루타민 및 알라닐-글루타민을 포함하는 안과용 조성물의 새로운 용도
HK1210968B (en) Compositions and treatment for eye diseases and disorders
CA3093371A1 (en) Methods of use and pharmaceutical compositions of a selective syk inhibitor

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20190613

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
AMND Amendment
A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20190719

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191113

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200217

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20191113

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20200217

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200109

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190718

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20200515

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20200417

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200217

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20200109

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190718

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200522

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200522

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20230418

Start annual number: 4

End annual number: 6